Search Results for: PTPN11

Novel Symbol Description Pathways Hide Drugs Hide Diseases Hide
CALR calreticulin
  • ER-Phagosome pathway
  • Assembly of Viral Components at the Budding Site
  • Scavenging by Class A Receptors
  • Scavenging by Class A Receptors
  • Scavenging by Class F Receptors
  • Scavenging by Class F Receptors
  • ATF6 (ATF6-alpha) activates chaperone genes
  • Calnexin/calreticulin cycle
  • Antigen Presentation: Folding, assembly and peptide loading of class I MHC
  • Antihemophilic factor, human recombinant
  • Tenecteplase
  • Melatonin
  • Lanoteplase
  • Copper
  • Calcium citrate
  • Calcium Phosphate
  • Lonoctocog alfa
  • Moroctocog alfa
  • Calcium phosphate dihydrate
CAT catalase
  • Detoxification of Reactive Oxygen Species
  • Neutrophil degranulation
  • Peroxisomal protein import
  • Peroxisomal protein import
  • FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes
  • Mitochondrial unfolded protein response (UPRmt)
  • Fomepizole
  • Cannabidiol
  • Benzoyl peroxide
  • Medical Cannabis
  • Nabiximols
  • Acatalasia, including: Acatalasemia; Takahara's disease; Hypocatalasemia
CAV1 caveolin 1
  • Triglyceride catabolism
  • eNOS activation
  • NOSTRIN mediated eNOS trafficking
  • Thyroxine biosynthesis
  • Basigin interactions
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • VEGFR2 mediated vascular permeability
  • RHOA GTPase cycle
  • Extra-nuclear estrogen signaling
  • RHOB GTPase cycle
  • RHOC GTPase cycle
  • CDC42 GTPase cycle
  • RAC1 GTPase cycle
  • RAC2 GTPase cycle
  • RHOD GTPase cycle
  • RHOQ GTPase cycle
  • RHOH GTPase cycle
  • RHOG GTPase cycle
  • RHOJ GTPase cycle
  • RAC3 GTPase cycle
  • RHOF GTPase cycle
  • FOXO-mediated transcription of cell cycle genes
  • RND3 GTPase cycle
  • RND2 GTPase cycle
  • RND1 GTPase cycle
  • SARS-CoV-1 targets host intracellular signalling and regulatory pathways
  • SARS-CoV-2 targets host intracellular signalling and regulatory pathways
  • Congenital generalized lipodystrophy (CGL)
CBL Cbl proto-oncogene
  • Interleukin-6 signaling
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • Spry regulation of FGF signaling
  • Regulation of KIT signaling
  • EGFR downregulation
  • TGF-beta receptor signaling activates SMADs
  • Constitutive Signaling by EGFRvIII
  • Negative regulation of FGFR1 signaling
  • Negative regulation of FGFR2 signaling
  • Negative regulation of FGFR3 signaling
  • Negative regulation of FGFR4 signaling
  • Negative regulation of MET activity
  • PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1
  • Cargo recognition for clathrin-mediated endocytosis
  • Clathrin-mediated endocytosis
  • InlB-mediated entry of Listeria monocytogenes into host cell
  • InlB-mediated entry of Listeria monocytogenes into host cell
  • Regulation of signaling by CBL
  • Regulation of signaling by CBL
  • Signaling by CSF1 (M-CSF) in myeloid cells
  • Negative regulation of FLT3
  • FLT3 signaling by CBL mutants
  • Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
CCKBR cholecystokinin B receptor
  • Peptide ligand-binding receptors
  • G alpha (q) signalling events
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • Pentagastrin
  • Cholecystokinin
CD33 CD33 molecule
  • Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
  • Neutrophil degranulation
  • Gemtuzumab ozogamicin
  • AVE9633
CDC73 cell division cycle 73
  • Formation of RNA Pol II elongation complex
  • Formation of the beta-catenin:TCF transactivating complex
  • Hedgehog 'on' state
  • RNA Polymerase II Pre-transcription Events
  • RNA Polymerase II Transcription Elongation
  • E3 ubiquitin ligases ubiquitinate target proteins
  • Primary hyperparathyroidism; Familial hyperparathyroidism (HRPT)
CDH5 cadherin 5
  • Adherens junctions interactions
  • VEGFR2 mediated vascular permeability
  • High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells
  • Lenalidomide
  • FX06
CEACAM1 CEA cell adhesion molecule 1
  • Fibronectin matrix formation
  • Cell surface interactions at the vascular wall
  • Neutrophil degranulation
  • Regulation of MITF-M dependent genes involved in invasion
  • Technetium Tc-99m arcitumomab
CHUK component of inhibitor of nuclear factor kappa B kinase complex
  • Activation of NF-kappaB in B cells
  • Activation of NF-kappaB in B cells
  • ER-Phagosome pathway
  • NOD1/2 Signaling Pathway
  • TICAM1, RIP1-mediated IKK complex recruitment
  • RIP-mediated NFkB activation via ZBP1
  • AKT phosphorylates targets in the cytosol
  • Downstream TCR signaling
  • FCERI mediated NF-kB activation
  • TAK1-dependent IKK and NF-kappa-B activation
  • Regulation of TNFR1 signaling
  • TNFR1-induced NF-kappa-B signaling pathway
  • IKBKB deficiency causes SCID
  • IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR)
  • IkBA variant leads to EDA-ID
  • Dectin-1 mediated noncanonical NF-kB signaling
  • CLEC7A (Dectin-1) signaling
  • Constitutive Signaling by AKT1 E17K in Cancer
  • NIK-->noncanonical NF-kB signaling
  • MAP3K8 (TPL2)-dependent MAPK1/3 activation
  • Interleukin-1 signaling
  • TRAF6 mediated NF-kB activation
  • NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10
  • IRAK1 recruits IKK complex
  • IKK complex recruitment mediated by RIP1
  • SARS-CoV-2 activates/modulates innate and adaptive immune responses
  • IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation
  • Regulation of NF-kappa B signaling
  • PKR-mediated signaling
  • SLC15A4:TASL-dependent IRF5 activation
  • Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells
  • Modulation of host responses by IFN-stimulated genes
  • Aminosalicylic acid
  • Mesalazine
  • Acetylcysteine
  • Cocoon syndrome
CRKL CRK like proto-oncogene, adaptor protein
  • Frs2-mediated activation
  • Frs2-mediated activation
  • Downstream signal transduction
  • MET activates RAP1 and RAC1
  • MET receptor recycling
  • Erythropoietin activates RAS
  • Erythropoietin activates RAS
  • Regulation of signaling by CBL
CSF2RB colony stimulating factor 2 receptor subunit beta
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • RAF/MAP kinase cascade
  • Surfactant metabolism
  • Defective CSF2RB causes SMDP5
  • Defective CSF2RA causes SMDP4
  • Interleukin receptor SHC signaling
  • Sargramostim
  • NPI 32101
  • Resatorvid
CSF3R colony stimulating factor 3 receptor
  • Other interleukin signaling
  • Transcriptional regulation of granulopoiesis
  • Signaling by CSF3 (G-CSF)
  • Signaling by CSF3 (G-CSF)
  • Inactivation of CSF3 (G-CSF) signaling
  • Inactivation of CSF3 (G-CSF) signaling
  • Pegfilgrastim
  • Filgrastim
  • FavId
  • Lenograstim
  • Lipegfilgrastim
  • Eflapegrastim
CTDSP1 CTD small phosphatase 1
  • Aspartate beryllium trifluoride
  • Citric acid
CTLA4 cytotoxic T-lymphocyte associated protein 4
  • Co-stimulation by CD28
  • Co-inhibition by CTLA4
  • RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs)
  • Abatacept
  • Ipilimumab
  • Tremelimumab
  • Graves' disease
  • Allograft rejection
  • Type I diabetes mellitus
  • Hashimoto's thyroiditis
CXCR4 C-X-C motif chemokine receptor 4
  • Binding and entry of HIV virion
  • Signaling by ROBO receptors
  • Chemokine receptors bind chemokines
  • G alpha (i) signalling events
  • Formation of definitive endoderm
  • Specification of primordial germ cells
  • Developmental Lineage of Multipotent Pancreatic Progenitor Cells
  • Baclofen
  • Framycetin
  • AMD-070
  • Plerixafor
  • Ulocuplumab
  • Ibalizumab
  • MSX-122
  • Chemokine receptor defect, including the following disease: WHIM syndrome
DAB1 DAB adaptor protein 1
  • Reelin signalling pathway
DDR1 discoidin domain receptor tyrosine kinase 1
  • Non-integrin membrane-ECM interactions
  • Imatinib
  • Fostamatinib
  • Pralsetinib
DMRTC1 DMRT like family C1
EGFR epidermal growth factor receptor
  • Signaling by ERBB2
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • Signaling by ERBB4
  • SHC1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • PLCG1 events in ERBB2 signaling
  • PIP3 activates AKT signaling
  • Signaling by EGFR
  • GRB2 events in EGFR signaling
  • GAB1 signalosome
  • SHC1 events in EGFR signaling
  • EGFR downregulation
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • EGFR interacts with phospholipase C-gamma
  • EGFR Transactivation by Gastrin
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Signal transduction by L1
  • Constitutive Signaling by EGFRvIII
  • Inhibition of Signaling by Overexpressed EGFR
  • RAF/MAP kinase cascade
  • ERBB2 Regulates Cell Motility
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • ERBB2 Activates PTK6 Signaling
  • Cargo recognition for clathrin-mediated endocytosis
  • Clathrin-mediated endocytosis
  • PTK6 promotes HIF1A stabilization
  • Downregulation of ERBB2 signaling
  • TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
  • Extra-nuclear estrogen signaling
  • NOTCH3 Activation and Transmission of Signal to the Nucleus
  • HCMV Early Events
  • Estrogen-dependent nuclear events downstream of ESR-membrane signaling
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Respiratory syncytial virus (RSV) attachment and entry
  • Developmental Lineage of Mammary Gland Myoepithelial Cells
  • Cetuximab
  • Lidocaine
  • Gefitinib
  • Erlotinib
  • Lapatinib
  • Panitumumab
  • Alvocidib
  • IGN311
  • Matuzumab
  • Vandetanib
  • Rindopepimut
  • Canertinib
  • Pelitinib
  • Varlitinib
  • AV-412
  • S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE
  • PD-168393
  • Afatinib
  • Osimertinib
  • Necitumumab
  • Foreskin keratinocyte (neonatal)
  • Depatuxizumab mafodotin
  • Icotinib
  • Neratinib
  • Dacomitinib
  • Fostamatinib
  • Poziotinib
  • Zalutumumab
  • Brigatinib
  • Olmutinib
  • Zanubrutinib
  • Abivertinib
  • Mobocertinib
  • Almonertinib
  • Amivantamab
  • Laryngeal cancer
  • Cervical cancer
  • Oral cancer
  • Gastric cancer
  • Choriocarcinoma
  • Esophageal cancer
  • Glioma
  • Bladder cancer

Page 2 out of 9 pages